Eltrombopag

L01EX10(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiamzonine-1-one 120685-11-2 9829523 5702 DB06595 8005258 ID912S5VON D05029 ChEMBL608533 DTXSID40923522 Interactive image C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC‍‍‍‍‍‍​​​‍​​​​​​=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1Key:BMGQWWVMWDBQGC-IIFHNQTCSA-N Midostaurin, sold under the brand nameRydaptbyNovartis, is a multi-targetedprotein kinase inhibitorthat has been investigated for the treatment ofacute myeloid leukemia(AML),myelodysplastic syndrome(MDS) and advancedsystemic mastocytosis. It is a semi-synthetic derivative ofstaurosporine, analkaloidfrom the bacteriumStreptomycesstaurosporeus. The USFood and Drug Administration(FDA) considers it to be afirst-in-class medication.